32936-76-8

Basic information

• Product Name: 1-Methylcyclobutanecarboxylic acid
• Synonyms: 1-Methylcyclobutanecarboxylic acid;1-Methylcyclobutane-1-carboxylic acid
• CAS NO: 32936-76-8
• Molecular Formula: C₆H₁₀O₂
• Molecular Weight: 114.14
• Mol File: 32936-76-8.mol

Chemical Properties

• Boiling Point: 203℃
• Flash Point: 92℃
• Appearance: /
• Density: 1.122
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 5.00±0.20(Predicted)
• CAS DataBase Reference: 1-Methylcyclobutanecarboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Methylcyclobutanecarboxylic acid(32936-76-8)
• EPA Substance Registry System: 1-Methylcyclobutanecarboxylic acid(32936-76-8)

Safety Data

• RIDADR: 3265
• HazardClass: 8
• PackingGroup: Ⅲ
• Hazardous Substances Data: 32936-76-8(Hazardous Substances Data)

Usage

Uses

1-Methylcyclobutanecarboxylic Acid is used for acid chlorination.

Upstream product

• 3721-95-7 Cyclobutanecarboxylic acid 
• 14924-53-9 ethyl cyclobutylcarboxylate 
• 65338-28-5 ethyl 1-methylcyclobutanecarboxylate 
• 74-88-4 methyl iodide 
• 42260-62-8 6a-Hydroperoxy-3a-methyl-tetrahydro-cyclopenta[1,2]dioxol-3-one 
• 124-38-9 carbon dioxide 
• 500335-38-6 1-methyl-cyclobutanecarboxylic acid amide 
• 42260-66-2 6a-Hydroxy-3a-methyl-tetrahydro-cyclopenta[1,2]dioxol-3-one 

Downstream Products

• 915710-15-5 methyl 4'-[10-(1-methylcyclobutan-1-ylmethoxy)decyloxy]biphenyl-4-carboxylate 
• 915710-16-6 methyl 4'-[11-(1-methylcyclobutan-1-ylmethoxy)undecyloxy]biphenyl-4-carboxylate 
• 82322-88-1 1-(cyclohexylacetyl)-1-methylcyclobutane 
• 80605-94-3 1-Methylcyclobutylmethylketoxim-pikrat 
• 98775-14-5 1-(bromo-methyl)-1-methyl-cyclobutane 
• 55368-89-3 1-(1-methylcyclobutyl)ethan-1-one 
• 21890-91-5 1-Methyl-1-(4-methoxy-benzoyl)-cyclobutan 

Relevant articles and documents

An immunomodulator

The present invention discloses an immunomodulator, specifically relates to a class of compounds inhibiting IL-17A and its use as an immunomodulator in the preparation of drugs. The present invention discloses a compound shown in formula I, or a stereoisomer thereof in the preparation of inhibiting IL-17A class of drugs, for clinical screening and / or preparation of drugs associated with IL-17A activity related to the drug provides a new option.

Immunomodulator

The invention provides an immunomodulator, and belongs to the field of medical chemistry. The immunomodulator is a compound represented by formula I, or a stereoisomer, or a salt, or a solvate, or a prodrug, or a metabolite thereof. The compound disclosed by the invention shows good IL-17A inhibitory activity, can be used for preparing an IL-17A inhibitor, is used for treating diseases with abnormal IL-17A activity, and the invention provides a new medicinal possibility for clinically treating diseases related to abnormal IL-17A activity.

Immunomodulator

The invention discloses an immunomodulator, and particularly relates to a compound shown as a formula I, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. Experiments prove that the compound has good IL-17A inhibitory activity, can be used for preparing an IL-17A inhibitor and drugs for preventing and/or treating IL-17A mediated diseases (such as inflammation, autoimmune diseases, infectious diseases, cancers and precancerous syndromes), and provides a new medical possibility for clinical treatment of diseases related to abnormal IL-17A activity.

Immunomodulator

The invention discloses an immunomodulator, and particularly relates to a compound for inhibiting IL-17A and application of the compound serving as the immunomodulator in preparation of drugs. The invention discloses application of a compound shown in a formula I or a stereoisomer thereof in preparation of medicines for inhibiting IL-17A, and provides a new choice for clinically screening and/or preparing medicines for treating diseases related to IL-17A activity.

Synthesis of Vicinal Quaternary All-Carbon Centers via Acid-catalyzed Cycloisomerization of Neopentylic Epoxides

We report our studies on the development of a catalytic cycloisomerization of 2,2-disubstituted neopentylic epoxides to produce highly substituted tetralins and chromanes. Termination of the sequence occurs via Friedel-Crafts-type alkylation of the remote (hetero)arene linker. The transformation is efficiently promoted by sulfuric acid and proceeds best in 1,1,1,3,3,3-hexafluoroisopropanol (HFIP) as the solvent. Variation of the substitution pattern provided detailed insights into the migration tendencies and revealed a competing disproportionation pathway of dihydronaphthalenes.

Nickel-catalyzed directed sulfenylation of sp2 and sp3 C-H bonds

Directed sulfenylation of both sp2 and sp3 C-H bonds was achieved through nickel catalyzed directed C-S bond formation, giving the desired product in good to excellent yield (up to 90%). Other metal cations, including Cu, Fe, Pd, Rh, Ru and Co, gave almost no reaction under identical conditions, which highlighted the unique reactivity of this Ni system.

N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities

Described are compounds of Formula I which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.

N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities

Described are compounds of Formula 1 which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.

β-Arylation of carboxamides via iron-catalyzed C(sp3)-H bond activation

A 2,2-disubstituted propionamide bearing an 8-aminoquinolinyl group as the amide moiety can be arylated at the β-methyl position with an organozinc reagent in the presence of an organic oxidant, a catalytic amount of an iron salt, and a biphosphine ligand at 50 C. Various features of selectivity and reactivity suggest the formation of an organometallic intermediate via rate-determining C-H bond cleavage rather than a free-radical-type reaction pathway.

AKT INHIBITORS

The present invention provides AKT inhibitors of the formula: Formula I The present invention also provides pharmaceutical compositions comprising compounds of Formula I, uses of compounds of Formula I and method of using compounds of Formula I.